Left Ventricular hypertrophy is outlined as an increase in the mass of the left ventricle, which may also be secondary to an expand in wall thickness, and broaden in cavity measurement. Left ventricular hypertrophy more often than not develops steadily. Whilst ventricular hypertrophy happens naturally as a response to aerobic undertaking and strength coaching, it is most commonly known as a pathological response to cardiovascular disorder, or high blood stress.
Treatment for LVH focuses on the underlying the cause of the condition. Depending on the cause, Treatment may include medication or surgery. Doctor suggests the treatment for LVH such as regular exercise a low-sodium, low-fat diet and no smoking. They used to control the blood pressure by using some types of drugs like enalapril (Vasotec), lisinopril (Prinivil, Zestril) and captopril (Capoten), atenolol (Tenormin), carvedilol (Coreg), metoprolol (Toprol XL) and bisoprolol (Zebeta) and etc.
Left ventricular mass index values (mean +/- SD) were 137 +/- 28 g/m2 in patients with the DD genotype, 125 +/- 27 g/m2 in those with the ID genotype and 115 +/- 27 g/m2 in those with II genotype. The frequencies of the DD, ID and II genotypes were 45.71% (n = 64), 46.42% (n = 65) and 7.85% (n = 11), respectively, and were in Hardy-Weinberg equilibrium. The strongest association between left ventricular mass and DD genotype in our cohort appeared to be an independent cardiovascular risk factor (DD vs. ID: odds ratio [OR] 2.497, 95% confidence interval [CI] interval 1.158 to 5.412, p < 0.05; DD vs. II: OR 6.577, 95% CI 1.169 to 28.580, p < 0.02).